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Activation of plasminogen on the cell surface initiates a cascade of protease activity with important implications for
several physiological and pathological events. In particular, components of the plasminogen system participate in
tumor growth, invasion and metastasis. Plasminogen receptors are in fact expressed on the cell surface of most
tumors, and their expression frequently correlates with cancer diagnosis, survival and prognosis. Notably, they can
trigger multiple specific immune responses in cancer patients, highlighting their role as tumor-associated antigens.
In this review, three of the most characterized plasminogen receptors involved in tumorigenesis, namely Annexin 2
(ANX2), Cytokeratin 8 (CK8) and alpha-Enolase (ENOA), are analyzed to ascertain an overall view of their role in the
most common cancers. This analysis emphasizes the possibility of delineating new personalized therapeutic
strategies to counteract tumor growth and metastasis by targeting plasminogen receptors, as well as their potential
application as cancer predictors.
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ImmunotherapyIntroduction
The plasminogen system is involved in tumor growth, inva-
sion and metastasis [1-5]. Several proteins of this system
have now been demonstrated to have a clinical value as
diagnostic and prognostic markers in many types of cancer
[6-11]. Overexpression of plasminogen receptors has been
associated with poor prognosis, shorter patient survival and
resistance to chemotherapy. Notably, this over-expression
may lead to the production of autoantibodies in many types
of cancers, which can be consequently used as tumor bio-
markers. Moreover, most plasminogen system components
are cell surface-expressed and therefore represent readily
accessible targets for cancer therapy. This review aims to
analyze the plasminogen receptors Annexin 2 (ANX2),
Cytokeratin 8 (CK8) and alpha-Enolase (ENOA) in the
most common tumors and to correlate their expression
with specific immune responses and/or clinical outcomes.* Correspondence: franco.novelli@unito.it
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Plasminogen is a 90kDa glycoprotein produced by the
liver and present in plasma and extracellular fluids [12-15].
It possesses seven structural domains: an N-terminal
activation peptide (1–77 aa), five kringle domains and a
serine-protease domain (562–791 aa). The kringle domains
mediate plasminogen binding to substrates and to cell
surface receptors [13,16] whereas the activation of plas-
minogen to plasmin is mediated by the proteolytic action
of either tissue-type (tPA) or urokinase-type (uPA) plas-
minogen activators [2,4,17,18]. Plasmin is a serine protease
with a broad-spectrum substrate, including fibrin, extracel-
lular matrix components (laminin, fibronectin) and pro-
teins involved in extracellular matrix degradation (matrix
metalloproteinases, such as MMP3) [16,19-22]. Binding of
plasminogen to surface receptors has profibrinolytic conse-
quences: enhancement of plasminogen activation, protec-
tion of plasmin from its inhibitor a2-antiplasmin and
enhancement of the proteolytic activity of cell-bound plas-
min [4,23-25]. Proteolysis mediated by cell-associated plas-
min contributes both to physiological processes, such as
tissue remodeling and embryogenesis, and to pathophysio-
logical processes, such as cell invasion, metastasis and
inflammatory responses [2-4,26-28]. A noteworthy positiveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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activation and malignancy [2,29].
Plasminogen receptors bind plasminogen by carboxy-
terminal lysines, and this common recognition motif
results in a similar affinity of plasminogen for most of
its receptors (Kd ≈ 1μM). Although many plasminogen
receptors have been described so far [30-43], the most
well-known plasminogen receptors shown to play a role
in cancer are ANX2, CK8 and ENOA. Interaction of
the plasminogen lysine binding sites with ENOA and
CK8 is dependent upon recognition of three C-terminal
lysines [23,40]. For ENOA, an additional internal plas-
minogen binding site, which includes Lys256, has been
proposed [44]. On the other hand, ANX2 harbors internal
amino acids that mimic C-terminal lysines and therefore
requires cleavage prior to binding plasminogen [45].
Molecular features of plasminogen receptors
ANX2 is a 36 kDa peripheral membrane protein (p36)
that belongs to the Annexin family, consisting of calcium-
dependent phospholipid-binding proteins with various
membrane-related functions [46-48]. ANX2 either exists
as a monomer, a heterodimer or a heterotetramer, the lat-
ter being composed of two copies of a 36 kDa heavy chain
(p36) and two copies of an 11 kDa light chain (p11). For-
mation of the Anx2 heterotetramer facilitates its binding
to the plasma membrane [45,48,49].
CK8 is an intermediate filament protein that polymerizes
with CK18 to form a component of the epithelial cytoskel-
eton [50]. In addition to its cytoplasmic localization it can
also be expressed on the cell surface [51,52] where it is
localized to the blebs of the cell membrane and acts as a
plasminogen receptor [53].
ENOA (2-phospho-D-glycerate hydrolase) was initially
discovered as a metalloenzyme that catalyzes the dehydra-
tion of 2-phospho-D-glycerate (PGA) to phosphoenolpyr-
uvate (PEP) in the glycolytic pathway [54,55]. In vertebrates,
the enzyme has three different isoforms (alpha, beta, and
gamma) codified by three independent loci. While ENOA is
mostly ubiquitous, beta- and gamma-enolase are almost
exclusively found in muscle and in neuronal tissues, respect-
ively [54,56,57]. ENOA can form homo- or heterodimers,
such as alpha-alpha, alpha-beta and alpha-gamma [58,59].
Both homo- and heterodimers can be expressed on the cell
surface where they act as plasminogen receptors.
Interestingly ANX2, CK8 and ENOA amino acid se-
quences lack a transmembrane portion, and the mechanism
by which they are displayed on the cell surface remains un-
known. Several mechanisms have been proposed for the
cell surface expression, including lipid binding followed by
translocation to the outer membrane [60]; penetration and
projection through the plasma membrane as a part of a
protein complex [52,61]; and non-covalent association to
the cell membrane after proteolytic release from cells intothe extracellular space [62-64]. In the case of ANX2 and
ENOA, post-translational modifications, such as acylation,
acetylation, methylation and phosphorylation, particularly
common in tumor cells, may also play a role [65-67].
Expression and function of ANX2 in cancer
ANX2 is physiologically expressed on the surface of epi-
thelial cells, vascular endothelial cells and macrophages
and is not only involved in plasminogen activation but
also in many biological processes that include inflamma-
tion, cell proliferation, angiogenesis, cell–cell interactions
and membrane bridgings, exocytosis and endocytosis, cell
growth and apoptosis [48,68-73]. All these functions are
due to its ability to interact with actin filaments in the
cytoskeletal system, to locate proteases and other extracel-
lular matrix components (plasminogen-plasmin-tPA) on
the cell surface through tetramerization, or by acting as a
major substrate for phosphorylation and as a second mes-
senger of growth-mediating receptor [49]. Indeed, ANX2
is phosphorylated on Tyr23, Ser11 and Ser25 residues by
c-Src, v-Src and Protein Kinase C (PKC), respectively
[74-76] after activation of insulin receptor [77], insulin
growth factor regulator [78], platelet-derived growth
factor-R [79], fibroblast growth factor (FGF) or epidermal
growth factor (EGF) [80]. Therefore, ANX2 may play a
role as a second messenger for transduction of growth
and differentiation.
During oncogenic transformation, ANX2 is usually up-
regulated and is a marker of aggressiveness in the majority
of cancer types (Table 1) [68,81-101]. As a result, it is a
valuable tool for cancer diagnosis. In fact, in hepato-cellular
carcinoma (HCC), ANX2 has been proposed as a differen-
tial diagnostic marker, in combination with glypican-3
(GPC3), glutamine synthetase (GS) and heat shock pro-
tein 70 (HSP70) [65,85,86,90,93,98,100-104]. ANX2 down-
regulation has also been reported in certain cancers,
such as laryngeal and esophageal squamous cell carcin-
oma, head and neck dysplasia [105-109], osteosarcoma
[110] and prostate cancer [111-113] (Table 1). In osteo-
sarcoma and oral carcinoma, ANX2 overexpression is
generally associated with well-differentiated tumors and,
in certain cases, ANX2 down-regulation was observed in
poorly-differentiated cancer which may be due to its abil-
ity to promote differentiation independently from its
plasminogen-binding function [107,110]. Indeed, in oral
carcinoma two different groups have reported an in-
creased expression of ANX2 in tumor tissue compared to
the surrounding normal mucosa or mucosa from patients
without oral cancer [100,107]. Rodrigo et al. also added a
clinical correlation analysis in which the lower expression
of ANX2 seemed to correlate with a poor prognosis. Even
if these studies appear controversial, both groups reported
that in poorly differentiated tumors, which usually correl-
ate with a bad prognosis, ANX2 was down-regulated. We
Table 1 Expression, immune response, clinical correlation and function of ANX2 in cancer
Cancer tissue Expression Immune
response
Clinical correlation Function
Bone protein [110] Metastasis [110]
Brain protein [97,98] Diagnosis [98]
Breast mRNA [99] Chemoresistance, Growth, Metastasis
[99,114-116,118]
Colon mRNA, protein [86,89,96] Prognosis [86]
Gastric protein [85] Prognosis [85]
Head and neck mRNA, protein [100]
[105-109]
Ab [119,120] Prognosis [100]
Hematopoietic
system
mRNA [95] protein [68,91] Growth, Metastasis [68,91]
Kidney protein [84,101] Survival, Prognosis [101] Metastasis [121]
Liver mRNA, protein
[88,90,92,93]
Diagnosis, Prognosis
[90,93,103]
Lung protein [82] Ab [122] Growth, Metastasis [117]
Ovary Ab [123]
Pancreas mRNA, protein [81,87] Ab [65,124] Survival, Prognosis [65,104] Chemoresistance, EMT, Metastasis [65,104]
Prostate protein [102,111-113] Prognosis [102] Growth, Metastasis [47,102]
Skin T cells [125]
Thyroid mRNA [83,94]
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oral carcinoma, but microenvironment and inflammatory
responses related to the anaplastic condition induce
down-regulation of ANX2 during cancer progression. Op-
posite trends reported ANX2 as a suitable prognostic
marker in HCC, renal (CRCC), colorectal and gastric car-
cinomas, where its expression negatively correlates with a
favorable clinical outcome [85,93,96,100,101]. In fact,
when up-regulated, ANX2 contributes to cancer invasion
and metastasis by acting as a co-receptor for plasminogen,
tPA and pro-cathepsin B [49]. ANX2-dependent plasmin
generation is required for invasion, metastasis and angio-
genesis in several cancer types [47,65,68,114-117]. For ex-
ample, it has been demonstrated that in pancreatic cancer
(PDAC), tyrosine 23 phosphorylation is necessary for cell-
surface localization of ANX2. This translocation is critical
for the Transforming Growth Factor beta (TGFbeta)-
induced, Rho-mediated epithelial-to-mesenchymal transi-
tion (EMT) [65]. Moreover, in PDAC, ANX2 overexpression
is a predictor of rapid recurrence after surgery in patients
who have undergone gemcitabine-adjuvant chemotherapy
[104]. In conclusion, we can hypothesize that in tumors
where ANX2 is overexpressed, its role as a plasminogen re-
ceptor predominates, and is responsible for the metastatic
process, while in tumors where ANX2 is down-regulated,
plasminogen-independent mechanisms favor the malignant
state through anaplastic transformation.Expression and function of CK8 in cancer
Several mechanisms have been proposed for the expression
of CK8 on the cell surface. In transformed cells, surface ex-
pression could be due to insufficient incorporation into
intermediate filaments due to over-production of CK8 [64].
Indeed, CK8 is over-expressed both at the mRNA and the
protein level in various carcinomas (Table 2) and is present
at the cell surface of several human cancers and established
tumor cell lines [51,52,64,88,126-129]. By contrast, healthy
human tissues do not express CK8 at the cell surface, with
the exception of a sporadic and weak CK8 membrane
localization in the liver and heart [127,130].
When present on the cancer cell surface, CK8 binds
plasminogen and promotes its activation through plas-
minogen activators. In breast cancer cells it also works
as a receptor for uPA [134], suggesting a model in which
CK8, in complex with uPA, plasminogen and fibronectin
constitutes a signaling platform capable of modulating
cell adhesion and growth. Indeed, increased expression
of CK8/CK18 has been shown at the invasive front of
certain tumors [145]. Of particular note, over-expression
of CK8 on the tumor cell surface and in the cytoplasm
correlates, both in vitro and in vivo, with increased inva-
siveness and metastatic properties [144]. In breast and
endometrial cancer, a clear correlation exists between
CK8 expression and tumor stage [133,144], and CK8
confers drug resistance to chemotherapeutic treatment
Table 2 Expression, immune response, clinical correlation and function of CK8 in cancer
Cancer tissue Expression Immune
response
Clinical correlation Function
Breast protein [52,64,127,131] Ab [132] Prognosis, Survival, Diagnosis
[131,133]
Chemoresistance, Growth, Metastasis
[134-136]
Colon Ab [137]
Gastric mRNA [128] Ab [138]
Head and
neck
protein [51] Ab [51,139]
Liver mRNA, protein [52,88] Ab [140,141] Prognosis [130]
Lung mRNA, protein
[126,129]
Survival [126,142]
Skin Metastasis [143]
Uterus Prognosis [144] Metastasis [144]
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over-expression on survival remains controversial as in
non-small cell lung carcinomas (NSCLC), increasing
serum levels of CK8 were significantly associated with
tumor progression and lower patient survival [126,142],
whereas breast cancer patients with low expression of
CK8 and high expression of Human Epidermal Growth
Factor Receptor 2 (HER2) have a higher risk of recur-
rence and death within 5 years (Table 2) [131].
Expression and function of ENOA in cancer
ENOA over-expression is associated with tumor devel-
opment through a process known as aerobic glycolysis
or the Warburg effect [146], which determines an
increase in anaerobic glycolysis in hypoxic conditions, a
very common feature in most solid tumors, but also inTable 3 Expression, immune response, clinical correlation and
Cancer Tissue Expression Immune response
Brain mRNA [152]
Bone protein [170]
Breast mRNA, protein [164,167,177] Ab [178,179]
Colon mRNA, protein [152,158,168]
Gastric mRNA, protein [152,162,169] T cells [180]
Head and neck mRNA, protein [155,166,171] Ab [119,120]
Hematopoietic
system
protein [160] Ab [181]
Liver mRNA, protein [130,152,156,165]
Lung mRNA, protein
[152,159,172,174,182]
Ab [159,172,178,183,1
Ovary mRNA, protein [152,153]
Pancreas mRNA, protein [152,154,161,163] Ab and T cells
[154,185,186]
Prostate mRNA, protein [152,187]
Skin mRNA [173] Ab [173,188]the presence of normal levels of oxygen [147-149]. The
ENOA promoter contains a hypoxia responsive element
[150,151] that leads to self up-regulation at both the
mRNA and protein levels (Table 3) [130,152-173]. How-
ever, in a small fraction of NSCLC [174], ENOA expres-
sion is down-regulated and, interestingly, is a gene that
can be homozygously absent in tumors [175]. In PDAC,
ENOA is not only up-regulated but is also subjected to
specific post-translational modifications, namely acetyl-
ation, methylation and phosphorylation which do not
occur in normal tissue [67,176].
Moreover, ENOA is expressed on the surface of
hematopoietic cells, such as monocytes, T cells, B cells
and neutrophils according to their activation status or
pathophysiological conditions [54]. ENOA is localized
on the cell surface of PDAC, breast and lung cancersfunction of ENOA in cancer
Clinical correlation Function
Prognosis [170]
Prognosis, Survival [167,178] Chemoresistance, Metastasis
[167,177,178]
Prognosis [166] Metastasis [166]
Prognosis [156,165] Growth, Metastasis [156]
84] Prognosis, Survival
[172,174,178]
Survival [185]
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NSCLC it is also secreted by exosomes [190,191]. On cell
surfaces, ENOA is part of a multi-protein complex, to-
gether with uPA receptor (uPAR), integrins and certain
cytoskeletal proteins, collectively known as a metastasome,
responsible for adhesion, migration and proliferation, as
clearly demonstrated in ovarian cancer cells [192]. More-
over, since ENOA interacts with the cytoskeleton in muscle
cells, its over-expression is likely to promote migration of
tumor cells by providing ATP [29]. Noteworthy, in human
follicular thyroid carcinoma cells, retinoic acid causes a de-
crease in ENOA levels that coincides with their reduced
motility [193], while cell surface ENOA is enhanced in
breast cancer cells rendered super-invasive following pacli-
taxel treatment [194].
The prognostic value of ENOA expression has been
observed in several tumors (Table 3) [156,165-167,170,
172,174,178,185]. In breast cancer, enhanced ENOA ex-
pression correlates with a greater tumor size, poor nodal
status and a shorter disease-free interval. Higher expres-
sion of ENOA increases the risk of longer distance relapse
when compared to loco-regional relapse in postsurgical
4-Hydroxytamoxifen-treated Estrogen Receptor-positive
breast cancer patients. Therefore, down-regulation of
ENOA could be a novel pharmacological approach for
overcoming 4-Hydroxytamoxifen resistance in breast can-
cer therapy [167]. In head and neck cancer and NSCLC,
ENOA levels increase with cancer progression and nega-
tively correlate with patients’ overall- and progression-free
survival [166]. In HCC, ENOA expression is up-regulated
in poorly differentiated tumors compared to well-
differentiated ones, and its levels positively correlate with
tumor size and venous invasion [156,165]. Even if ENO1
are not currently used in clinical routine, the altered ex-
pression or the induced immune response, as show later,
may have a prognostic/diagnostic value, especially in com-
bination with gold-standard markers. For example, in
PDAC, the detection of serum antibodies against phos-
phorylated ENOA, in combination with the commonly
used serum marker CA19.9, enhances the ability to dis-
criminate between control and cancer patients [185].
Taken together, these findings determine that ENOA is a
good biomarker to monitor tumor progression and to pre-
dict clinical outcome.
Plasminogen receptors elicit immune responses in cancer
Activation of the immune system is an early event dur-
ing tumorigenesis, as illustrated by the detection of high
titers of autoantibodies in patients with early-stage can-
cer, and correlates with the progression of malignant
transformation [119,195,196]. The presence of an im-
mune response to the plasminogen receptors ANX2,
CK8 and ENOA has been reported in patients with dif-
ferent types of cancer.An autoantibody response against ANX2 occurs in the
early stages of gingivo-buccal carcinogenesis and in PDAC,
ovarian, and lung cancer (Table 1) [65,119,120,122,123]. It
has been demonstrated that in melanoma, the ANX2
(208–223) peptide induces antigen-specific T cells, which
can recognize cancer cells over-expressing the ANX2
molecule. This peptide may therefore be useful in immuno-
therapy for recruiting CD4+ type 1 helper cells locally
active in the tumor environment [125]. Moreover, phase II
clinical trial PDAC patients [124] showed an increased
anti-ANX2 antibody response after administration of the
GM-CSF (granulocyte-macrophage colony-stimulating fac-
tor) PDAC-specific vaccine, which positively correlated
with prolonged survival [65].
CK8/18 complexes elicit humoral responses in breast,
gastric, colon, head and neck and liver carcinomas
[51,132,137-141]. In squamous cell carcinoma (SCC), ele-
vated titers of CK8-specific serum antibodies are detectable
in early stage patients, while a weaker humoral response
has been observed in advanced patients, probably due to
immunosuppression by tumor cells. In several adenocar-
cinomas, patients develop an immune response against tu-
moral neo-epitopes of CK8 [137], while head and neck and
lung cancer patients develop autoantibodies against post-
translationally modified variants of the protein (Table 2)
[139,142]. The induction of specific antibodies against CK8
can be explained by its ectopic expression on the cancer
cell surface that makes CK8 a potential candidate for
antibody-based cancer therapy.
A humoral and/or T cell immune response against
ENOA has been observed in patients with breast, head
and neck, gastric, lung cancer, chronic myeloid leukemia,
melanoma and PDAC (Table 3) [119,120,154,159,172,173,
178-181,183-186,188]. Notably, detection of autoantibodies
against ENOA combined with expression of carcino-
embryonic antigen (CEA) and CK19 fragment enhances
the sensitivity for differential diagnosis of NSCLC [184].
High levels of antibodies to phosphorylated ENOA were
found in PDAC, and their combination with the serological
marker CA19.9 discriminates patients from controls [185].
The presence of the humoral response to phosphorylated
ENOA also correlates with a longer progression-free
survival upon gemcitabine treatment and overall survival
[185] and notably, with the presence of a specific T cell
response [154,180,186,197]. Conversely, a marked decrease
in basal levels of ENOA-autoantibodies is a common event
in late lung and breast cancers, proposing ENOA-
autoantibodies as a prognostic marker to monitor disease
progression in these patients [178].
Plasminogen receptors as therapeutic targets in cancer
Despite heterogeneous numbers of plasminogen re-
ceptors existing in eukaryotic cells, only ENOA, CK8
and ANX2 have a recognized role in human cancer
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invasion. ANX2 also behaves as a tPA receptor, whilst
ENOA and CK8 do not directly bind plasminogen acti-
vators, but most likely form a multi-protein complex
with uPAR and integrins [64,67]. Nevertheless, the con-
tribution of these three receptors to cancer development
is not only linked to their plasminogen-binding capacity.
Indeed ANX2, ENOA and CK8 all interact with the
actin cytoskeleton and such an association could pro-
mote the migration of tumor cells independently from
plasminogen-binding [29]. These three receptors are
present on the surface of the majority of human neo-
plasms, and in some cases, such as breast and colon,
they are expressed altogether. All of these receptors
elicit an antibody immune response in cancer patients
that can be potentially boosted for therapeutic purposes.
Regarding the potential risk of inducing an autoimmune
reaction, CK8 would probably be the best candidate as it
is aberrantly expressed only on the tumor cell surface.
However, even the ANX2 and ENOA are frequently
over-expressed by tumor cells and exposed on the cell
surface. This strengthens the hypothesis for utilizing
them as potential targets of therapeutic monoclonal
antibodies. Notably, data obtained in animal models
show a therapeutic effect of anti-ANX2 monoclonal
antibody (mAb) treatment in breast, pancreatic and lung
cancer by inhibiting tumor growth, suppressing metasta-
ses and prolonging survival (Table 1) [65,114,117]. Thus,
blocking plasminogen receptors is a promising strategy
to counteract metastasis development.
A recent paper has shown that a DNA-based vaccin-
ation against human ENOA, followed by electroporation,
was able to significantly prolong the median of life expect-
ancy of mice that spontaneously develop PDAC [186]. In-
deed, the ENOA DNA vaccine induced both a humoral
and cellular response. Autoantibodies against ENOA were
able to bind the cell surface of PDAC murine cells and
mediate their killing by complement-dependent cytotox-
icity. This “immunogenic” death might be responsible for
the greater influx of CD3 into tumor and for their activa-
tion toward Th1/Th17 phenotype. Cytokines produced by
these Th populations strongly supported the “effecto”
switching of anti-ENOA autoantibodies [186]. Moreover,
the ENOA-DNA vaccine significantly decreased suppres-
sor cells such as myeloid-derived suppressor cells and
regulatory T cells [186].
Conclusions
Overall, with very few exceptions, all three plasminogen
receptors reported here display performant diagnostic
and prognostic values. Since one single receptor type is
not expected to account for the entire plasminogen
binding on tumor cells, a combined therapy targeting
all these molecules would be desirable. Nevertheless,further studies are necessary in order to better under-
stand the involvement of these three receptors in cancer
progression, so that more effective strategies for cancer
treatment may be developed.
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